<DOC>
	<DOCNO>NCT01827930</DOCNO>
	<brief_summary>The Imatinib Mesylate dose 400 mg / day standard treatment patient CML-CP . Recent study show quality response rate ( complete cytogenetic response major molecular response rate ) dependent residual plasma Imatinib .</brief_summary>
	<brief_title>Phase III Trial Evaluating Effectiveness Dose Adjustment Imatinib Mesylate Molecular Response</brief_title>
	<detailed_description>The Imatinib Mesylate dose 400 mg / day standard treatment patient CML-CP . Recent study show quality response rate ( complete cytogenetic response major molecular response rate ) dependent residual plasma Imatinib . This study aim evaluate effectiveness strategy dose adjustment Imatinib Mesylate base measurement residual plasma imatinib patient treat least 2 year Imatinib 400 mg / complete cytogenetic response least 1 year .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients CMLCP treat least two year Imatinib Mesylate 400 mg / , 2 . Patients complete cytogenetic response least 1 year 3 . Patients residual disease detectable quantitative RTPCR ( RQPCR ) 4 . ECOG ≤ 2 , 5 . Age ≥ 18 year 6 . Signed informed consent , 7 . Membership social security system 1 . Patients CMLCP Philadelphia chromosome negative diagnosis . 2 . Patients previously treat Imatinib Mesylate dose 400 mg / day 3 . Patient nonhematologic toxicity grade III IV Imatinib Mesylate 400mg / 4 . Patient medical condition endocrine , psychiatric , neurological , renal , hepatic cardiac progressive uncontrolled medical treatment 5 . Pregnant breastfeed woman , woman childbearing potential use contraceptive method effective 6 . Known HIV positive 7 . Patients previously treat another tyrosine kinase inhibitor 8 . Patient participate another interventional clinical trial 9 . History noncompliance Imatinib Mesylate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chronic myeloid leukemia chronic phase</keyword>
</DOC>